The debate over what counts as an 'AI drug'

After Shkreli’s comments on a live All-In podcast revived the discussion, a post argues against treating “AI drugs” and “regular drugs” as separate categories. It points to older machine-learning methods used to turn sequencing data into useful signals and to screen molecules. The author expects newer methods to become routine, too, and argues that tracking when an “AI drug” will be approved starts from a false premise.